Pemetrexed as second-line chemotherapy for castration-resistant prostate cancer after docetaxel failure: Results from a phase II study

Orazio Caffo, Lucia Fratino, Roberto Barbieri, Alessandra Perin, Thomas Martini, Teodoro Sava, Romana Segati, Emanuela Vaccher, Franco Bernardo Bassan, Antonello Veccia, Giovanni Pappagallo, Enzo Galligioni

Research output: Contribution to journalArticlepeer-review

Abstract

Objective: Although there is no standard treatment after docetaxel failure in patients with castration-resistant prostate cancer (CRPC), second-line chemotherapy is increasingly required. Its mechanism of action and toxicity profile make pemetrexed suitable for testing in this setting. Methods and materials: Patients with docetaxel-resistant CRPC received pemetrexed 500 mg/m2 every 3 weeks for 6 courses. The usual premedication with vitamin supplementation and dexamethasone prophylaxis was regularly administered. The primary objective was to quantify the biochemical response rate. Results: The biochemical response rate was 10.5% (95% CI 1.3-33.1), with 2 patients showing a reduction in prostate specific antigen (PSA) of ≥50%. The null hypothesis that the PSA response rate would be less than 20% was therefore accepted, and patient accrual was stopped after the evaluation of the 19th patient. The 1-year overall survival rate was 61.5%, with a median survival of 14 months. A considerable proportion of the patients (36%) were withdrawn from the study because of hematologic and nonhematologic toxicity. Conclusions: Our experience with pemetrexed in CRPC patients appears discouraging in terms of activity and toxicity. No further studies of this drug should be performed in CRPC patients.

Original languageEnglish
Pages (from-to)180-186
Number of pages7
JournalUrologic Oncology: Seminars and Original Investigations
Volume31
Issue number2
DOIs
Publication statusPublished - Feb 2013

Keywords

  • Castration-resistance
  • Pemetrexed
  • Prostate cancer
  • Second line chemotherapy

ASJC Scopus subject areas

  • Oncology
  • Urology

Fingerprint Dive into the research topics of 'Pemetrexed as second-line chemotherapy for castration-resistant prostate cancer after docetaxel failure: Results from a phase II study'. Together they form a unique fingerprint.

Cite this